Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the four analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $98.75.
A number of equities research analysts recently weighed in on the company. StockNews.com cut Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. Finally, DA Davidson boosted their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th.
Check Out Our Latest Research Report on PBH
Institutional Inflows and Outflows
Prestige Consumer Healthcare Stock Down 0.2 %
PBH opened at $73.55 on Wednesday. The company has a market capitalization of $3.65 billion, a PE ratio of 17.64, a price-to-earnings-growth ratio of 2.06 and a beta of 0.48. The firm has a 50-day simple moving average of $70.98 and a two-hundred day simple moving average of $69.61. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 52 week low of $56.34 and a 52 week high of $75.80.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million for the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.06 earnings per share. Analysts forecast that Prestige Consumer Healthcare will post 4.42 earnings per share for the current fiscal year.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- Quiet Period Expirations Explained
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Are the FAANG Stocks and Are They Good Investments?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.